Testosterone derivative

Abstract

The invention is the novel androgen (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4en-3one (MENT undecanoate). This compound distinguishes favourably from other testosterone derivatives in that it has a good solubility in oily media. It particularly exhibits a good dissolved potency relative to testosterone. The compound is particularly suitable for administration by means of injection.

We claim:  
     
         1 . A kit for male contraception, comprising: 
 a means for the administration of a progestagen and    a means for the administration of an androgen,    wherein the latter means is a pharmaceutical formulation, comprising: 
 (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4-en-3-one and  
 a pharmaceutically acceptable carrier.  
   
     
     
         2 . The kit for male contraception according to  claim 1 , wherein the pharmaceutically acceptable carrier is a liquid in which (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4-en-3-one is dissolved.